Halda Therapeutics has entered into a collaboration with VantAI in a deal valued at more than $1 billion. The agreement is structured around the use of VantAI’s machine learning and proteomics technologies to supply Halda with novel target-effector pairs that can be incorporated into its regulated induced proximity targeting chimeras (RIPTACs). These bifunctional small molecules are being developed to address cancer and immune-mediated diseases. Throughout the article, the Halda Therapeutics VantAI RIPTAC deal will be referenced.
Halda was founded by Yale University professor Craig Crews, Ph.D., who previously played a central role in the creation of PROTACs. While PROTACs function by tagging disease-causing proteins for degradation, RIPTACs operate differently. The molecules work by bringing together a tumor-specific protein with a second protein that is essential for the survival of healthy cells. When this complex is formed inside a cancerous cell, the essential protein is inhibited. This inhibition, occurring only in cells that also carry the tumor-specific protein, can lead to the selective elimination of tumors—all central to the Halda Therapeutics VantAI RIPTAC deal approach.
The approach depends on Halda having access to both tumor-specific proteins and essential proteins. This is the contribution of VantAI, which will apply its Neo-1 foundation learning model and its NeoLink high-throughput proteomics platform to discover and validate novel target-effector pairs. These pairs are the fundamental building blocks of RIPTAC molecules. VantAI has previously applied its discovery platform to other related modalities, such as molecular glues and protein degraders, in partnerships with Blueprint Medicines, Bristol Myers Squibb, and Johnson & Johnson. This strengthens the significance of the Halda Therapeutics VantAI RIPTAC deal.
Halda’s platform is intended to address limitations associated with older modalities. Traditional oncology drugs usually inhibit a protein that cancer cells rely on for growth or proliferation. By contrast, RIPTACs, like antibody-drug conjugates, use the tumor-specific protein simply as a targeting mechanism. In this way, RIPTACs are able to kill cells by disrupting the activity of essential proteins rather than by interfering with oncogenic pathways, opening up more of the cancer proteome to therapeutic intervention under the Halda Therapeutics VantAI RIPTAC deal.
The biotech has described this method as a “hold-and-kill” mechanism. Its efficacy lies in the fact that inactivating essential proteins can kill a cell, but the cytotoxic effect is directed specifically to cancerous cells because the presence of a tumor-specific protein is required. Halda is testing this concept through its lead candidate, HLD-0915. The oral RIPTAC drug is in a phase 1/2 clinical trial for metastatic castration-resistant prostate cancer. These tumors frequently become resistant by increasing expression of the androgen receptor, but HLD-0915 uses that mechanism against the tumor by binding the androgen receptor along with another protein involved in transcription regulation. The Halda Therapeutics VantAI RIPTAC deal enables access to many more target-effector pairs, which could accelerate candidates beyond HLD-0915.
Financial details of the collaboration were not fully disclosed. A spokesperson for VantAI confirmed in an email to BioSpace that the agreement includes a “meaningful” upfront payment, milestone payments across multiple programs, and eligibility for tiered royalties on net sales of products if they reach the market. The spokesperson stated only that the deal is structured in a way that could yield VantAI more than $1 billion in total, without providing a breakdown of the figures. This financial scope is central to the Halda Therapeutics VantAI RIPTAC deal’s potential impact.
VantAI’s chief executive officer, Zachary Carpenter, highlighted the broader impact of the partnership. In a prepared statement, he said, “Halda’s approach, dubbed induced proximity, is poised to unlock a new and exciting chapter of medicine.” Carpenter also emphasized that his company’s AI capabilities would enable rational drug design and open the door to “previously inaccessible targets.” The Halda Therapeutics VantAI RIPTAC deal is seen as a signal that drug discovery is increasingly pushing into novel modalities.
While oncology remains the immediate focus, Halda and VantAI also plan to apply the RIPTAC platform to immune-mediated diseases.
Additional Content Added on the Halda Therapeutics VantAI RIPTAC Deal
Beyond the core cancer programs, the Halda Therapeutics VantAI RIPTAC deal is expected to influence how target discovery is done in smaller biotech firms. VantAI’s NeoLink platform gives speed and scale, enabling rapid structural proteomics screening in contexts where traditional methods are slow or resource-intensive.
Investors are also watching the Halda Therapeutics VantAI RIPTAC deal to see how regulatory bodies respond to new modality classes. With HLD-0915 already in phase 1/2 clinical development, upcoming data readouts on safety, specificity, and off-target effects will be scrutinized, especially as the partnership expands into immunology domains.
In addition, this agreement could set a precedent for how AI-driven proteomics and machine learning tools are funded and adopted. Academic institutions involved in cancer biology have expressed interest in collaborating with VantAI or Halda through shared discovery efforts, hoping the Halda Therapeutics VantAI RIPTAC deal may open data-sharing and licensing pathways.
Finally, follow-on RIPTAC programs may layer on biomarkers to select patients whose tumors express both the targeting protein and the effector partner. Personalized medicine thus becomes more feasible under this model. The Halda Therapeutics VantAI RIPTAC deal isn’t just about one drug; it could evolve the whole class of proximity-based therapeutics.
